Exploiting epigenetic vulnerabilities for cancer therapeutics. by Mair, B, Kubicek, S, Nijman, S

Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity by Mair, B, Konopka, T, Kerzendorfer, C, Sleiman, K, Salic, S, Serra, V, Muellner, M, Theodorou, V, Nijman, S

Crisis care for children and young people with mental health problems: national mapping, models of delivery, sustainability and experience (CAMH-Crisis2). A study protocol. [versio... by Rachael Vaughan, Clare Bennett, Mair B Elliott, Ben Hannigan, Nicola Evans, Martin Elliott, Euan Hails, Claire Fraser, Iain McMillan, Aled Jones, Leanne Sawle, Steven Pryjmachuk

Get full text

Discovery of a highly selective cell‐active inhibitor of the histone lysine demethylases KDM2/7 by Gerken, P, Wolstenhume, J, Tumbler, A, Hatch, S, Zhang, Y, Muller, S, Chandler, S, Mair, B, Li, F, Nijman, S, Konietzny, R, Szommer, T, Yapp, C, Fedorov, O, Benesch, J, Vedadi, M, Kessler, B, Kawamura, A, Brennan, P, Smith, M

Discovery of a highly selective cell-active inhibitor of the histone lysine demethylases KDM2/7 by Gerken, PA, Wolstenhulme, JR, Tumber, AM, Hatch, SB, Zhang, Y, Müller, S, Chandler, SA, Mair, B, Li, F, Nijman, SMB, Konietzny, R, Szommer, T, Yapp, C, Fedorov, O, Benesch, JLP, Vedadi, M, Kessler, BM, Kawamura, A, Brennan, PE, Smith, MD